Gilead Sciences GILD has entered into licensing deals with six pharmaceutical companies to manufacture and supply a cheaper ...

Gilead Sciences is granting licenses to six companies to produce lenacapavir for pre-exposure prophylaxis, as well as for ...

Gilead will license the HIV drug lenacapavir, a twice-yearly injectable, to six generic makers for 120 countries.

A drug currently used to treat HIV has also been found to dramatically reduce the risk of infection, significantly more than the primary option available for pre-exposure prophylaxis or PrEP. In a ...

A new report finds there is a decline in condom usage because of access to other contraceptives and drugs that prevent STIs.

A single laboratory-based HIV viral load test used by U.S. clinicians who provide people with long-acting, injectable cabotegravir (CAB-LA) HIV pre-exposure prophylaxis (PrEP) did not reliably ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Pemivibart (Pemgarda) should only be used for pre-exposure prophylaxis of COVID-19 in immunocompromised patients when ...

HIV PrEP medications are usually prescribed by PCPs; however, adherence to PrEP varies by clinician specialty due to the different populations served.

Pharmaceutical firm Hetero has partnered with Gilead Sciences Ireland UC to manufacture and distribute the HIV treatment drug lenacapavir in 120 primarily low- and lower-middle-income countries. The ...

Lenacapravir is a major advance, since it provides a highly effective PrEP option that can be delivered subcutaneously twice a year.